MRKRHealthcare · BiotechnologyThe 3 Wall Street analysts covering Marker Therapeutics, Inc. hold a median 12-month price target of $8 — +700.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 27 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Marker Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (88): Smaller than most of the companies we track.
Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MRKR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +700.0% from it.
Of the 19 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Dec 2025 | HC Wainwright & Co. | Initiates | Buy | $10 |
| 1 Apr 2025 | WBB Securities | Reiterates | Strong Buy | — |
| 5 Mar 2025 | Canaccord Genuity | Initiates | Buy | — |
| 21 Oct 2024 | Ladenburg Thalmann | Maintains | Buy | $11 → $19 |
| 30 Apr 2024 | Ladenburg Thalmann | Initiates | Buy | — |
| 17 Feb 2022 | Roth Capital | Downgrade | Neutral | $3.00 → $1.00 |
| 25 Mar 2021 | Piper Sandler | Initiates | Overweight | — |
| 19 Mar 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 18 Mar 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 12 May 2020 | Piper Sandler | Downgrade | Neutral | $5.00 → $2.50 |
| 13 Nov 2019 | Janney Capital | Maintains | Buy | — |
| 13 Nov 2019 | Janney Montgomery Scott | Maintains | Buy | $15 → $10 |
| 13 Nov 2019 | Piper Jaffray | Maintains | Overweight | — |
| 13 Nov 2019 | Piper Sandler | Maintains | Overweight | $10 → $6.00 |
| 3 July 2019 | Oppenheimer | Initiates | Outperform | — |
| 30 May 2019 | Roth Capital | Initiates | Buy | — |
| 29 Mar 2019 | WBB Securities | Upgrade | Strong Buy | — |
| 1 Mar 2019 | Janney Capital | Initiates | Buy | — |
| 1 Mar 2019 | Janney Montgomery Scott | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MRKR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Marker Therapeutics, Inc. returned −1.0% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 26% of US stocks
Cheaper than 60% of US stocks
Cheaper than 65% of US stocks
Higher than 9% of US stocks
Higher than 2% of US stocks
Higher than 16% of US stocks
Higher than 10% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Marker Therapeutics, Inc. has a market value of $15.8M and an enterprise value of $4.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$8.7M.
Free cash flow in the twelve months to 30 June 2026: −$9.8M.
Trailing P/E: −1.2×; forward P/E: −1.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Marker Therapeutics, Inc. employs 5 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Marker Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Marker Therapeutics announced it was awarded $2.6 million from the FDA’s Orphan Products Clinical Trials grants program. The headline says the grant will advance MT-601 in pancreatic cancer.
Why it matters — The FDA grant provides funding for Marker’s development of MT-601 in pancreatic cancer.
Marker Therapeutics (MRKR) was upgraded to Zacks Rank #1 (Strong Buy), reflecting growing optimism about its earnings prospects.
Why it matters — MRKR watchers may note the improved Zacks rating as an indicator of increased optimism about the company's earnings prospects.
Zacks Investment Research reported that MRKR was added to its Zacks Rank #1 (Strong Buy) List on October 16, 2026, alongside UGP, SCSC, SLGL and MEOH.
Why it matters — MRKR watchers may note its inclusion on Zacks’ Strong Buy list.
Marker Therapeutics, Inc. highlighted the expanded infrastructure, technical expertise, and manufacturing capabilities supporting its lead program MT-601 (neldaleucel), following the combination of Cellipont Bioservices and Kincell Bio to form Kincellis Advanced Therapies. The company noted the strengthened CDMO support for its clinical-stage MAR-T cell therapy development.
Why it matters — MRKR watchers would care because enhanced manufacturing support from its CDMO partner strengthens the infrastructure behind its lead clinical program, MT-601.
The 3 Wall Street analysts covering Marker Therapeutics, Inc. have a median 12-month price target of $8, with estimates ranging from $5.6 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Marker Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Marker Therapeutics, Inc. 64 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Marker Therapeutics, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +700.0% from the last close, and Ticker Nerd's factor model ranks Marker Therapeutics, Inc. 64 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Marker Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRKR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.6 to $10 over the next 12 months.
Marker Therapeutics, Inc. returned -1.0% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies for blood cancers and solid tumors.
The most recent item we track (GlobeNewsWire, 19 Oct 2026): "Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer". Marker Therapeutics announced it was awarded $2.6 million from the FDA’s Orphan Products Clinical Trials grants program. The headline says the grant will advance MT-601 in pancreatic cancer.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies for blood cancers and solid tumors. Its core platform uses non-genetically engineered tumor-specific T cells designed to recognize multiple tumor-associated antigens, with the goal of creating broader anti-cancer activity. The company’s current pipeline includes product candidates such as MT-601, being studied in lymphoma and pancreatic cancer, and MT-401-OTS, being evaluated in acute myeloid leukemia and myelodysplastic syndromes. Marker Therapeutics also explores peptide-based vaccine approaches as part of its cancer treatment portfolio. Headquartered in Houston, Texas, the company operates in the biotechnology sector and serves the specialized area of cell therapy research and development, where its work supports the advancement of next-generation treatments for difficult-to-treat malignancies.
CEO Dr. Juan F. Vera M.D. · 5 employees · United States · https://markertherapeutics.com
